LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
TCRT
Alaunos Therapeutics, Inc.
There isn't enough reported data to score TCRT yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TCRT Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TCRT's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TCRT PE Valuation
TCRT has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TCRT Forward outlook
There aren't enough analyst estimates for TCRT to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TCRT on earnings quality, reporting a profit while its opponent remains loss making.
TCRT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.90 | +$0.51 |
| Q1 2026 | -$2.12 | +$0.37 |
| Q4 2025 | -$2.20 | +$0.72 |
| Q3 2025 | -$2.26 | +$4.25 |
| Q2 2025 | -$2.41 | +$9.40 |
| Q1 2025 | -$2.49 | +$14.61 |
| Q4 2024 | -$2.92 | +$19.08 |
| Q3 2024 | -$6.51 | +$15.99 |
TCRT is still losing money, but far less than before: $1.90 per share over the past year, against $105.00 at its worst in early 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over TCRT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
TCRT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $3K | -25% |
| Q1 2025 | $2K | +100% |
| Q4 2024 | $4K | +300% |
| Q2 2024 | $4K | 0% |
| Q4 2023 | $1K | -91% |
| Q3 2022 | $2.9M | +631% |
TCRT's revenue has slid since its 2022 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -30233% | -11358 points |
| Q1 2025 | -54600% | +119600 points |
| Q4 2024 | -18875% | +776025 points |
| Q2 2024 | -29150% | +170400 points |
| Q1 2024 | -174200% | N/A |
| Q4 2023 | -794900% | -717436 points |
| Q2 2023 | -199550% | N/A |
| Q4 2022 | -77464% | N/A |
TCRT's operating margin was −30233% last quarter, up 143967 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with TCRT at up 93%.
TCRT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$300K | +$401K |
| Q1 2026 | -$1M | -$259K |
| Q4 2025 | -$553K | +$39K |
| Q2 2025 | -$701K | +$980K |
| Q1 2025 | -$772K | +$1.1M |
| Q4 2024 | -$592K | +$6.8M |
| Q3 2024 | -$781K | +$5.6M |
| Q2 2024 | -$1.7M | +$5.5M |
TCRT has burned cash in almost every quarter: −$3M over the past year, against −$4M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TCRT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TCRT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +25% | +483K shares |
| 1 year | +45% | +755K shares |
| 3 years | +52% | +833K shares |
| 5 years | +70% | +1M shares |
| Available history | +114% | +1.3M shares |
TCRT has 2M diluted shares, up 45% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q4 2022 | — |
| Q4 2019 | $283,000 |
| Q3 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TCRT Net Leverage
TCRT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TCRT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.5 | Neutral |
| Stochastic | 28.6 | Neutral |
TCRT's weekly RSI is 45 (neutral) and its Stochastic is 29 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TCRT PE vs Healthcare Sector
| Metric | TCRT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TCRT has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TCRT on trend strength, trading above more of its moving averages.
TCRT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.61 | 0.6% above |
| 20 week MA | $1.73 | 6.4% below |
| 50 week MA | $2.43 | 33% below |
| 100 week MA | $2.50 | 35% below |
| 200 week MA | $17.4 | 91% below |
TCRT has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 91% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TCRT on returns for 2026, with the stronger performance.
TCRT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $772.5 | $432.0 | -44% |
| 2021 | $432.0 | $189.0 | -56% |
| 2022 | $189.0 | $88.2 | -53% |
| 2023 | $88.2 | $10.6 | -88% |
| 2024 | $10.6 | $1.84 | -83% |
| 2025 | $1.84 | $3.23 | +76% |
| 2026 YTD | $3.23 | $1.62 | -50% |
TCRT has finished lower in five of the last six years. It's down 50% so far in 2026.